Metformin Hydrochloride (Glucophage)

Metformin hydrochloride, sold by Bristol-Myers Squibb under the brand name Glucophage is the most prescribed drug for lowering blood sugar levels in people with type-2 diabetes. Generics are expected to be available in the U.S. in early 2002 - they've been available in Europe for decades (the drug was discoved in 1929).

BMS lobbied aggressively- but unsuccessfully - to extend its domestic monopoly until 2004; attempting to keep generics off the market by exploiting a loophole involving pediatric studies and data exclusivity. The Wall Street Journal summarizes the rationale for the extention as:

General Information on Metformin Hydrochloride



Lobbying Effort

Government Involvement in R&D
Generics to Be Introduced Introduced

News Stories

Return to: CPTech Home -> Main IP Page -> IP and Healthcare